Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

NCT03507998 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Adenocarcinoma
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma
Bile Duct Carcinoma
Hepatocellular Carcinoma
Esophageal Carcinoma
Gastrointestinal Cancer

Interventions

DRUG: CGX1321

Sponsor

Curegenix Inc.

Collaborators

[object Object]